<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Heart transplantation in adults: Diagnosis of allograft rejection</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Heart transplantation in adults: Diagnosis of allograft rejection</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Heart transplantation in adults: Diagnosis of allograft rejection</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Howard J Eisen, MD, FACC, FAHA, FHFSA, FAST</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sharon A Hunt, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 10, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H322698713"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Despite the use of potent immunosuppressive agents, acute cellular rejection (ACR) and antibody-mediated rejection (AMR) remain important problems in heart transplantation.</p><p>This topic discusses the clinical manifestations and diagnosis of acute cardiac allograft rejection. The treatment of ACR and AMR is discussed separately. (See  <a class="medical medical_review" href="/d/html/3520.html" rel="external">"Heart transplantation in adults: Treatment of rejection"</a>.)</p><p class="headingAnchor" id="H1"><span class="h1">INCIDENCE</span><span class="headingEndMark"> — </span>The incidence of rejection after transplantation influences the surveillance schedule for rejection. The incidence of each type of rejection after transplantation is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute cellular rejection</strong> – ACR is a common problem after heart transplantation, particularly during the first three to six months after transplantation:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a study that examined the incidence of ACR after discharge from transplantation surgery to one year, the incidence of moderate to severe ACR was 12 percent [<a href="#rid1">1</a>]. However, by excluding mild rejection and AMR, this statistic underrepresents the totality of rejection.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In another report that described the incidence of treated rejection in the first year after transplantation, the rate was 13 percent [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibody-mediated rejection</strong> – AMR (noncellular, vascular, humoral) is a poorly understood and infrequently diagnosed process that nonetheless leads to morbidity and mortality [<a href="#rid3">3,4</a>]. There is wide variation in the reported incidence of AMR among centers; unlike ACR, testing for AMR is not routine in most transplant centers [<a href="#rid5">5</a>]. In a review of 587 patients who underwent testing for AMR and ACR at a single center, 19 percent of rejection episodes were due to AMR alone, 60 percent were due to ACR alone, and 23 percent had mixed AMR and ACR [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1">Non-human leukocyte antigen-mediated AMR is a rare form of AMR.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mixed rejection</strong> – Due to the incomplete detection of AMR, the incidence of mixed rejection is poorly understood. Mixed rejection is present in 23 percent of patients who have rejection [<a href="#rid6">6</a>].</p><p></p><p class="headingAnchor" id="H146870426"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>Although rejection can occur in any heart transplant recipient, the likelihood of a rejection episode is influenced by several donor and recipient factors:</p><p class="bulletIndent1"><span class="glyph">●</span>Younger recipient [<a href="#rid7">7-9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Female recipient [<a href="#rid7">7,9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Female donor [<a href="#rid7">7-9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>More human leukocyte antigen (HLA) mismatches between the donor and recipient [<a href="#rid9">9-12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recipient antibodies against donor antigens (ie, donor-specific antibodies) that develop prior to or after transplantation, which is the main risk factor for AMR.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recipient antibodies against non-HLA, such as minor histocompatibility antigen (MHC) class I (MICA) [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nonadherence to immunosuppressive therapy, which may be a factor contributing to high rates of rejection in adolescents and young adults [<a href="#rid14">14,15</a>].</p><p></p><p class="headingAnchor" id="H6"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Acute rejection can be detected in otherwise asymptomatic patients who are undergoing routine surveillance testing, or it can manifest as signs and symptoms of cardiac dysfunction that range from mild heart failure (HF) and palpitations to cardiogenic shock and syncope. Infrequently, patients with ACR present with atrial arrhythmias [<a href="#rid16">16,17</a>]. Rarely, patients with rejection present with nonspecific extracardiac symptoms such as fever. The presentations of ACR and AMR are not distinct.</p><p>In otherwise asymptomatic patients who are undergoing biopsy with right heart catheterization, isolated hemodynamic abnormalities are an uncommon presentation of rejection.</p><p class="headingAnchor" id="H3546922067"><span class="h1">TESTS FOR REJECTION</span></p><p class="headingAnchor" id="H3559643123"><span class="h2">Endomyocardial biopsy</span><span class="headingEndMark"> — </span>Endomyocardial biopsy is considered the gold-standard for the detection of rejection. However, the distribution of ACR in the allograft is thought to be heterogenous or multifocal, and thus, endomyocardial biopsy is subject to sampling error [<a href="#rid18">18,19</a>]. Though the distribution of AMR is likely more homogenous than the distribution in ACR, the detection of AMR requires specialized staining for complement deposition that is subject to variability. For both types of rejection, there is considerable variation in pathologists’ interpretation of the results. (See <a class="local">'Pathologic diagnosis'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biopsy procedure</strong> – Endomyocardial biopsies are generally performed in a specialized facility, either a cardiac catheterization laboratory or a dedicated biopsy suite. Vascular access is obtained through the right internal jugular vein or, less commonly, through a femoral vein. In many programs, a right heart catheterization is performed and intracardiac pressures are recorded. Following right heart catheterization, a specialized cardiac bioptome similar to a bronchoscopic bioptome is then guided from the superior vena cava to the right atrium and across the tricuspid valve into the right ventricle (using fluoroscopy or, occasionally, echocardiography). (See  <a class="medical medical_review" href="/d/html/4923.html" rel="external">"Endomyocardial biopsy"</a>.)</p><p></p><p class="bulletIndent1">The bioptome is then used to obtain a minimum of three, and preferably four or more, evaluable specimens from the right ventricular septum [<a href="#rid20">20</a>]. Some samples may not be evaluable due to the presence of scar caused by previous biopsies. Most of the biopsy specimens are fixed immediately in 10 percent buffered formalin for light microscopy; tissue can also be frozen for immunohistochemical studies. Further details on specific tissue preparation are discussed elsewhere in this topic. (See <a class="local">'Pathologic diagnosis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications</strong> – The common complications of endomyocardial biopsy are discussed separately. (See  <a class="medical medical_review" href="/d/html/4923.html" rel="external">"Endomyocardial biopsy", section on 'Complications'</a>.)</p><p></p><p class="bulletIndent1">Tricuspid regurgitation (TR) is a complication that can occur in cardiac transplant recipients, and its most likely cause is repeated passes of the bioptome across the tricuspid valve during surveillance and other biopsy procedures [<a href="#rid21">21</a>], though other causes of TR in patients after transplantation include right ventricular dilation, distortion of the tricuspid valve ring due to size mismatch between the donor and recipient, and pulmonary hypertension after transplantation. The reported prevalence of TR ranges from 47 to 98 percent and is moderate to severe in up to one-third of patients [<a href="#rid21">21,22</a>].</p><p></p><p class="bulletIndent1">The evaluation and management of TR are discussed separately. (See  <a class="medical medical_review" href="/d/html/8119.html" rel="external">"Etiology, clinical features, and evaluation of tricuspid regurgitation"</a> and  <a class="medical medical_review" href="/d/html/8145.html" rel="external">"Management and prognosis of tricuspid regurgitation"</a>.)</p><p></p><p class="headingAnchor" id="H3769405346"><span class="h2">Gene expression profiling</span><span class="headingEndMark"> — </span>Gene expression profiling (GEP) is a test designed to noninvasively detect ACR by quantifying the expression of genes from circulating mononuclear cells obtained from peripheral blood. The most common GEP test records the expression of eleven genes and reports a score between 0 to 40 points; grade 2 R rejection is more likely at higher scores. Three of the genes in this GEP test are sensitive to the dose of steroids; high-dose steroids may result in a false negative result [<a href="#rid23">23</a>]. GEP tests were designed to detect ACR but may have some ability to detect AMR. The clinical use of GEP is described elsewhere in this topic. (See <a class="local">'Approaches to evaluating for rejection'</a> below.)</p><p>The diagnostic characteristics of GEP testing for ACR and AMR include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Identifying acute cellular rejection</strong> – GEP testing was designed to detect ACR. In general, the most common GEP test has a high negative predictive value and specificity but a low positive predictive value and sensitivity:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a study including 107 patients who were at least six months posttransplantation, genes for the detection of ACR were selected and validated [<a href="#rid23">23</a>]. The outcome of the study was the ability of GEP to distinguish between grade 0 (termed "quiescence") and moderate to severe rejection (grade ≥3A in the 1990 system; classified as ≥2 R in the 2004 system). In the validation sample of patients who were more than one year after transplantation, a GEP score threshold of &lt;30 points had a negative predictive value of 99.6 percent and a positive predictive value of 6.8 percent for moderate to severe ACR.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a subsequent study of the same GEP test described above but with a cutoff GEP score of ≥35 points to identify grade 2 R ACR, the sensitivity and specificity were 10 percent and 96 percent, respectively, while the negative predictive and positive predictive values were 98 and 3 percent, respectively [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Identifying antibody-mediated rejection</strong> – The ability of GEP to detect AMR is not as well-studied compared with its ability to detect ACR. In a derivation study that included 55 patients with AMR and 55 patients without AMR, a panel of genes was selected to optimize detection of AMR from tissue obtained from endomyocardial biopsy. In the validation cohort of 27 cases of AMR and 71 controls, the diagnostic accuracy for each of the candidate transcripts ranged from an area under the curve of 0.80 to 0.86 [<a href="#rid25">25</a>]. Patients with AMR had evidence of endothelial activation, microcirculatory inflammation, and higher natural killer cell activity. These gene transcripts could identify the presence of AMR in endomyocardial biopsies and suggest the pathogenesis of AMR.</p><p></p><p class="headingAnchor" id="H3993194474"><span class="h2">Donor-derived cell-free DNA</span><span class="headingEndMark"> — </span>Donor-derived cell-free deoxyribonucleic acid (dd-CF DNA) is released from damaged donor heart cells and can be quantified relative to the amount of background circulating recipient cell-free DNA [<a href="#rid25">25-27</a>]. An increase in the percentage of dd-CF DNA in the blood indicates injury to the transplanted (ie, donor) heart that may be caused by ACR or AMR, as well as other forms of injury, such as cardiac allograft vasculopathy. The role of dd-CF DNA is described elsewhere in this topic. (See <a class="local">'Approaches to evaluating for rejection'</a> below.)</p><p>The accuracy of dd-CF DNA for the detection of ACR and AMR was reported in a large prospective study of 171 patients who had undergone transplantation at least seven days prior [<a href="#rid28">28</a>]. The study assessed the ability of dd-CF DNA to detect grade 2 R ACR or grade 1 AMR. The study reported the following:</p><p class="bulletIndent1"><span class="glyph">●</span>For the detection of ACR in patients who were at least 14 days posttransplantation, the sensitivity and specificity of dd-CF DNA were 83 and 82 percent, respectively, for the cutoff value of 0.25 percent dd-CF DNA.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For the detection of AMR in similar patients, the sensitivity and specificity of dd-CF DNA were 88 and 82 percent, respectively, for the cutoff value of 0.25 percent dd-CF DNA. For either AMR or ACR and at the 0.25 percent cutoff, the sensitivity and specificity were 88 and 82 percent, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Given the limitations of endomyocardial biopsy to detect ACR and AMR, the study also evaluated dd-CF DNA as the reference standard to assess the accuracy of endomyocardial biopsy. When dd-CF DNA ≥0.25 percent was used as the reference standard, the study found that endomyocardial biopsy had a sensitivity of 20 percent and specificity of 99 percent.</p><p></p><p class="headingAnchor" id="H2890221242"><span class="h1">APPROACHES TO EVALUATING FOR REJECTION</span></p><p class="headingAnchor" id="H329562200"><span class="h2">Surveillance in asymptomatic patients</span><span class="headingEndMark"> — </span>In asymptomatic patients who underwent cardiac transplantation in the last year, our approach to surveillance testing with endomyocardial biopsy and serologic testing is described in a table (<a class="graphic graphic_table graphicRef140149" href="/d/graphic/140149.html" rel="external">table 1</a>). This schedule may be modified to wean a patient from steroids more rapidly or in response to other significant changes in maintenance immunosuppression (eg, reduction of <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> levels to prevent kidney injury).</p><p>Some programs continue routine surveillance testing (eg, biopsies or serologic testing) every three to four months in the second year. Surveillance biopsies are rarely conducted beyond two years, though surveillance in this period for some patients with significant risk factors for rejection may be reasonable. (See <a class="local">'Risk factors'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Specifics of testing and interpretation</strong> – The details of testing and our approach to interpretation of test results are as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Endomyocardial biopsy</strong> – During each endomyocardial biopsy, we obtain samples to assess for ACR. In select patients (eg, history of donor-specific antibodies, past history of AMR), we assess for signs of AMR, though some programs routinely test for AMR. The diagnostic criteria for ACR and AMR are discussed elsewhere in this topic. (See <a class="local">'Diagnosis'</a> below.)</p><p></p><p class="bulletIndent2">The description of the endomyocardial biopsy procedure is described elsewhere. (See  <a class="medical medical_review" href="/d/html/4923.html" rel="external">"Endomyocardial biopsy", section on 'Technique'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Serologic testing</strong> – The preferred test for surveillance of asymptomatic patients is determined by the time after transplantation (<a class="graphic graphic_table graphicRef140149" href="/d/graphic/140149.html" rel="external">table 1</a>):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Two weeks to two months after transplantation</strong> – For asymptomatic patients between two weeks and two months after transplantation, we perform a donor-derived cell-free (dd-CF) DNA test. dd-CF DNA cannot be used earlier after transplantation due to the high levels of circulating donor DNA caused by the stresses of procurement and implantation. In contrast with gene expression profiling (GEP), dd-CF DNA test results are not influenced by high-dose steroids used in the months following transplantation. (See <a class="local">'Donor-derived cell-free DNA'</a> above and <a class="local">'Gene expression profiling'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Between two months and twelve months after transplantation</strong> – For asymptomatic patients who require surveillance testing within 2 to 12 months after transplantation, we use a GEP test and a dd-CF DNA test.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Beyond one year after transplantation</strong> – For asymptomatic patients who require surveillance testing 12 or more months after transplantation, we typically perform dd-CF DNA testing. ACR in this interval is rare, and dd-CF DNA testing can detect both ACR and AMR, while GEP can only detect ACR.</p><p></p><p class="bulletIndent2">After obtaining serologic tests for rejection, we perform confirmatory biopsies based on the test results as follows:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Simultaneous gene expression and cell free DNA test results</strong> –<strong> </strong>If a GEP test and dd-CF DNA are obtained simultaneously, the result of each test must be considered. If the dd-CF DNA result is positive, we obtain a biopsy regardless of the GEP result. If the dd-CF DNA result is negative and the GEP result is positive, the approach to performance of a biopsy is individualized and may be influenced by such factors as the severity and frequency of past episodes of rejection. If both tests are negative, we do not perform a biopsy. This approach is based on the diagnostic characteristics of these tests, as described elsewhere in this topic. (See <a class="local">'Gene expression profiling'</a> above and <a class="local">'Donor-derived cell-free DNA'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Isolated gene expression profiling</strong> –<strong> </strong>If an isolated GEP test is negative, we do not perform an endomyocardial biopsy. If an isolated GEP test is positive, we typically obtain a biopsy. In patients who have two negative biopsies following elevated GEP test results, we do not obtain further biopsies based on GEP results and cease GEP testing. This approach is motivated by the high negative predictive value and low positive predictive value of GEP testing, which is discussed elsewhere in this topic. (See <a class="local">'Gene expression profiling'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Isolated donor-derived cell-free DNA</strong> –<strong> </strong>In the presence of an isolated positive dd-CF DNA test, we obtain an endomyocardial biopsy, while a negative dd-CF DNA result does not require a follow-up biopsy. This approach is motived by the high diagnostic accuracy of the dd-CF DNA test, which is described elsewhere in this topic. (See <a class="local">'Donor-derived cell-free DNA'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evidence and rationale</strong> – The indication for rejection surveillance in the weeks and months early after transplantation is based on experience and potential for adverse outcomes caused by untreated allograft rejection. There is no true "gold standard" for the detection of ACR or AMR except pathologic examination. Endomyocardial biopsy is considered a standard for comparison but suffers from sampling variation and is invasive. (See <a class="local">'Endomyocardial biopsy'</a> above.)</p><p></p><p class="bulletIndent1">The use of serologic tests as substitutes for endomyocardial biopsy is motivated by the noninvasive nature of these tests and reasonable correlation with endomyocardial biopsy results:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gene expression profiling</strong> – While GEP has been compared with endomyocardial biopsy in two noninferiority trials, these trials have methodologic flaws, and it is unclear how to interpret a noninferiority trial in which the diagnostic accuracy of the reference test (ie, endomyocardial biopsy) is not well-established:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>The Invasive Monitoring Attenuation through Gene Expression (IMAGE) trial was performed as a noninferiority comparison between a GEP test and routine biopsies for a composite primary outcome of rejection with hemodynamic compromise, graft dysfunction due to other causes, death, or retransplantation [<a href="#rid29">29</a>]. The 602 patients were enrolled six months to five years following transplantation (85 percent received transplantation more than one year prior to enrollment). A mandatory biopsy was performed for a GEP test score of 30 (increased to a threshold of 34 midtrial). There was no significant difference in two-year cumulative rates of the composite outcome between the GEP and routine biopsy groups (14.5 and 15.3 percent; hazard ratio 1.04, 95% CI 0.67-1.68). However, this result is consistent with as high as a 68 percent increase in risk using the GEP strategy. More broadly, the results of the trial highlight the uncertainty around the efficacy of rejection surveillance of any type.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Early IMAGE was a single-center study that randomized 60 transplant patients from two to six months after transplant to either GEP or biopsy-guided therapy (30 patients in each group) [<a href="#rid30">30,31</a>]. It too was designed as a noninferiority comparison with the same primary composite endpoint as the original IMAGE trial. Early IMAGE also showed similar rates of the composite endpoint, though the study was not adequately powered to establish the noninferiority of GEP testing. The Early IMAGE study also showed that corticosteroids could be weaned during months 2 to 6 as effectively when guided by GEP as by biopsy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>dd-CF DNA</strong> – dd-CF DNA has higher sensitivity and specificity compared with GEP but has not been studied as extensively as GEP. (See <a class="local">'Gene expression profiling'</a> above and <a class="local">'Donor-derived cell-free DNA'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other tests</strong> – Alternatives to testing for rejection with endomyocardial biopsy, GEP, and dd-CF DNA include high-sensitivity troponin, B-type natriuretic peptide, echocardiography, cardiovascular magnetic resonance imaging, and imaging of radiolabeled tracers (eg, lymphocytes, antimyosin antibodies, annexin-V) [<a href="#rid32">32-42</a>]. While such tests correlate with histologic evidence of rejection, they are not used for surveillance of rejection or to confirm the diagnosis of rejection.</p><p></p><p class="bulletIndent2">Tests such as echocardiography and cardiac biomarkers are frequently used in the initial evaluation of patients with signs or symptoms of rejection to identify cardiac abnormalities that require further evaluation. The use of these tests in symptomatic patients is described elsewhere in this topic. (See <a class="local">'Symptomatic patients'</a> below.)</p><p></p><p class="bulletIndent1">The schedule for surveillance testing is based on the higher incidence of ACR in the months following transplantation surgery. After the incidence of ACR declines, surveillance for rejection is less likely to identify significant rejection, and the practice of surveillance biopsies in asymptomatic patients beyond the first year is controversial (see <a class="local">'Incidence'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A study of the Cardiac Transplant Research Database found no benefits from surveillance biopsy beyond five years posttransplant [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Evidence from the IMAGE study of subjects six months to five years posttransplant indicates that intermediate-term outcomes are similar between patients with asymptomatic and symptomatic rejection [<a href="#rid29">29</a>].</p><p></p><p class="headingAnchor" id="H1078327767"><span class="h2">Symptomatic patients</span><span class="headingEndMark"> — </span>In patients with any of the clinical manifestations of acute rejection, an initial evaluation is performed to assess the severity of suspected rejection (see <a class="local">'Clinical manifestations'</a> above). The initial evaluation typically includes:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>History and physical examination</strong> – The history and physical examination are focused on identifying any alterations to the immunosuppressive regimen, recent use of medications that may interact with immunosuppression, and the time course and nature of any HF, chest pain, or palpitations. Additionally, the examination should include an assessment for venous congestion (eg, elevated jugular venous pressure, leg edema), third heart sound, and signs of inadequate perfusion (eg, cool extremities).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory tests</strong> – Patients suspected of having rejection should have an assessment of electrolytes, kidney function, liver function, cell counts, and coagulation studies. In most patients, we obtain high-sensitivity troponin and B-type natriuretic peptide levels to evaluate for signs of myocardial injury and as a noninvasive measure of cardiac filling pressures, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Electrocardiogram</strong> – All patients suspected of rejection should have an electrocardiogram performed to evaluate for a change in rhythm or other signs of rejection (eg, loss of voltage).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Echocardiography</strong> – Echocardiography is typically obtained to assess for significant changes in ventricular function and elevated filling pressures.</p><p></p><p>Based on the initial evaluation, we take the following steps:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with risk factors or evidence of cardiac abnormalities</strong> – In symptomatic patients with a history of alterations to immunosuppression, evidence of new cardiac abnormalities on initial testing, or whose symptoms are unexplained and suspicious for rejection, we typically perform an endomyocardial biopsy to assess for rejection. In these patients, a GEP test or a dd-CF DNA test are not substitutes for an endomyocardial biopsy.</p><p></p><p class="bulletIndent1">In such patients, endomyocardial biopsy should be performed to assess for ACR and AMR.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients without risk factors or signs of new cardiac abnormalities</strong> – In patients in whom the initial evaluation does not reveal a history of disrupted immunosuppression (eg, cessation, interaction with drugs that decrease immunosuppression levels), new signs of cardiac dysfunction, or reveals a noncardiac cause for symptoms (eg, pneumonia), further testing is individualized.</p><p></p><p class="headingAnchor" id="H169143349"><span class="h2">Other indications for testing</span><span class="headingEndMark"> — </span>In patients who have changes to their immunosuppressive regimen (eg, dose reduction in <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> or glucocorticoids, change from tacrolimus to <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a>) or who have recovered from an episode of acute rejection, we typically perform an endomyocardial biopsy one to two weeks after the change in therapy or after the rejection event to assess for rejection [<a href="#rid43">43</a>]. In some patients with small changes in therapy or low-grade rejection, either a GEP test or a dd-CF DNA test is a reasonable alternative to endomyocardial biopsy.</p><p class="headingAnchor" id="H3844802544"><span class="h2">Surveillance during the COVID-19 pandemic</span><span class="headingEndMark"> — </span>As recommended by the International Society for Heart and Lung Transplantation, during the coronavirus disease 2019 (COVID-19) pandemic, for patients with stable allograft function and low risk of rejection (such as patients &gt;3 months from transplant with no recent history of rejection, who are not sensitized and lack a positive cross match), routine surveillance biopsies are deferred as clinically appropriate until local resources and capacity allow [<a href="#rid44">44</a>]. For patients with moderate or high risk of rejection, the benefits of surveillance biopsies are weighed against the risks of exposure to the patient and health personnel and limitations of available resources.</p><p class="headingAnchor" id="H7"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H3909324662"><span class="h2">Clinical diagnosis</span><span class="headingEndMark"> — </span>In patients who have undergone heart transplantation, the presence of new HF symptoms, unexplained arrhythmias, objective decline in cardiac function, or hemodynamic signs of acute rejection (eg, elevated filling pressures) suggests the presence of acute rejection. In patients with any of these findings, an initial evaluation and endomyocardial biopsy are typically required to confirm the diagnosis; though empiric treatment (eg, intravenous solumedrol 500 to 1000 mg per day) is often initiated before confirmation with an endomyocardial biopsy.</p><p class="headingAnchor" id="H4142289806"><span class="h2">Pathologic diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of rejection is confirmed by pathologic examination of myocardium sampled from an endomyocardial biopsy. The approach to testing for rejection is described elsewhere in this topic. (See <a class="local">'Approaches to evaluating for rejection'</a> above.)</p><p>The types of rejection that can be diagnosed and their criteria include:</p><p class="headingAnchor" id="H11"><span class="h3">Acute cellular rejection</span><span class="headingEndMark"> — </span>ACR is formally diagnosed by light microscopy of hematoxylin- and eosin-stained specimens on endomyocardial tissue. Morphologically, ACR manifests as a mononuclear inflammatory response, predominantly lymphocytic, that infiltrates the myocardium. In more severe cases, granulocytes are also seen [<a href="#rid20">20</a>]. Severe rejection is typically accompanied by evidence of cardiac myocyte injury or necrosis.</p><p>Cardiac transplant biopsies have been graded for ACR according to the standardized International Society for Heart and Lung Transplantation (ISHLT) nomenclature, which was introduced in 1990 [<a href="#rid45">45,46</a>] and revised in 2004 [<a href="#rid20">20</a>]. We prefer to use the 2004 system:</p><p class="bulletIndent1"><span class="glyph">●</span>Grade 0 – No rejection</p><p class="bulletIndent1"><span class="glyph">●</span>Grade 1 R, mild – Interstitial and/or perivascular infiltrate with up to one focus of myocyte damage</p><p class="bulletIndent1"><span class="glyph">●</span>Grade 2 R, moderate – Two or more foci of infiltrate with associated myocyte damage</p><p class="bulletIndent1"><span class="glyph">●</span>Grade 3 R, severe – Diffuse infiltrate with multifocal myocyte damage, with or without edema, hemorrhage, or vasculitis</p><p></p><p>The 2004 nomenclature can be mapped to the 1990 nomenclature, which is in use at most centers (<a class="graphic graphic_table graphicRef51982" href="/d/graphic/51982.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H15"><span class="h3">Acute antibody-mediated (humoral) rejection</span><span class="headingEndMark"> — </span>The diagnosis of AMR is based upon the following histologic features [<a href="#rid5">5,20,47</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Light microscopy demonstrates myocardial capillary injury with intravascular macrophage accumulation. Other findings may include intravascular thrombi and interstitial edema, hemorrhage, and neutrophilic infiltration in and around the capillaries.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Positive immunofluorescence or immunoperoxidase staining within the capillaries for immunoglobulins (eg, IgG, IgM, IgA), complement (C4d, C3d, and/or C1q), or CD68 staining of macrophages.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The histologic findings are commonly accompanied by serum antibodies directed against the donor’s human leukocyte antigen (HLA) class I and II antigens (ie, donor-specific antibodies). Such antibodies may arise de novo after transplantation or be preformed due to other exposures that include transfusion, pregnancy, and previous transplantation [<a href="#rid5">5,48</a>].</p><p></p><p>If all three of these features are present, the patient is diagnosed with AMR.</p><p>In patients who have evidence of capillary injury and complement deposition by immunofluorescence but who do not have measurable HLA antibodies to the donor, rejection may be caused by non-HLA antibodies [<a href="#rid5">5</a>]. In such patients, repeating the donor-specific antibody assay may be helpful to identify donor-specific antibodies. Antibodies also may be formed against a variety of non-HLA, although the role of these antibodies in AMR is not well defined, and they are not routinely measured in the clinical setting [<a href="#rid49">49,50</a>].</p><p>A nomenclature for the severity of pathologic AMR (pAMR) was developed in 2013 by the ISHLT [<a href="#rid51">51</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>pAMR 0: Negative for pathologic AMR – Both histologic and immunopathologic studies are negative.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>pAMR 1: Histopathologic AMR alone – Histologic findings present and immunopathologic findings negative.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>pAMR 1: Immunopathologic AMR alone – Histologic findings negative and immunopathologic findings positive.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>pAMR 2: Pathologic AMR – Both histologic and immunopathologic findings are present.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>pAMR 3: Severe pathologic AMR – This category recognizes the rare cases of severe AMR with histopathologic findings of interstitial hemorrhage, capillary fragmentation, mixed inflammatory infiltrates, endothelial cell pyknosis, and/or karyorrhexis and marked edema. The experience of the group was that these cases are associated with profound hemodynamic dysfunction and poor clinical outcomes.</p><p></p><p>The treatment of AMR is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/3520.html" rel="external">"Heart transplantation in adults: Treatment of rejection", section on 'Antibody-mediated rejection'</a>.)</p><p class="headingAnchor" id="H3401387408"><span class="h3">Nonrejection findings</span><span class="headingEndMark"> — </span>There are several processes that can produce cellular infiltration in the cardiac allograft and must be distinguished from acute rejection. The 2004 ISHLT revision included the following biopsy descriptions of nonrejection findings [<a href="#rid20">20</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ischemic injury</strong> – Ischemic injury can be seen soon after transplantation (up to six weeks posttransplant) and in patients with graft injury after (related to allograft coronary disease). Perioperative ischemic damage can cause myocardial necrosis as a result of donor trauma with catecholamine excess, pressor therapy during acute care, ex vivo organ ischemia, or reperfusion injury. The histologic appearance of ischemic damage early after transplant usually includes myocyte necrosis out of proportion to the cellular infiltrate, which is predominantly polymorphonuclear rather than mononuclear [<a href="#rid52">52</a>]. Later ischemic injury is related to allograft coronary disease, which is also called transplant vasculopathy. (See  <a class="medical medical_review" href="/d/html/3522.html" rel="external">"Heart transplantation: Clinical manifestations, diagnosis, and prognosis of cardiac allograft vasculopathy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Quilty effect</strong> – The Quilty effect describes the presence of one or more dense subendocardial monomorphic lymphocytic infiltrates, so called because they were first seen in a patient of that name [<a href="#rid53">53</a>]. Quilty lesions differ from rejection in two respects: They extend to the endocardial surface of the heart, and they include a substantial proportion of B lymphocytes. Quilty lesions are felt to have no clinical significance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection</strong> – Opportunistic infections such as cytomegalovirus (CMV) and toxoplasma myocarditis can produce lymphocytic infiltration in the allograft myocardium. These infections can be distinguished from rejection by the presence of characteristic CMV inclusion bodies in the lymphocytes or toxoplasma organisms in the myocardium [<a href="#rid54">54</a>]. (See  <a class="medical medical_review" href="/d/html/1396.html" rel="external">"Infection in the solid organ transplant recipient"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lymphoproliferative disorder</strong> – Rarely, posttransplant lymphoproliferative disorders (PTLDs) involve the heart, with myocardial infiltration of atypical lymphocytes [<a href="#rid55">55</a>]. Most PTLDs are due to malignant transformation of B lymphocytes; immunohistologic evaluation can distinguish such infiltrates from the predominantly T cell infiltrates of rejection. In addition, Epstein-Barr virus gene expression in these cells can often be detected using in situ hybridization. (See  <a class="medical medical_review" href="/d/html/7335.html" rel="external">"Treatment and prevention of post-transplant lymphoproliferative disorders"</a>.)</p><p></p><p class="headingAnchor" id="H18"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/16304.html" rel="external">"Patient education: Heart transplant (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/3439.html" rel="external">"Patient education: Heart transplantation (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H19"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – Rejection is more common early after transplant, though it can occur at any time. (See <a class="local">'Incidence'</a> above.)</p><p></p><p class="bulletIndent1">Although rejection can occur in any heart transplant recipient, the likelihood of a rejection episode is influenced by the time after transplantation as well as several donor and recipient factors (see <a class="local">'Risk factors'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Younger recipient, female recipient, female donor.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>More human leukocyte antigen (HLA) mismatches between the donor and recipient, recipient antibodies against donor antigens (ie, donor-specific antibodies).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Recipient antibodies against non-HLA, such as minor histocompatibility antigen (MHC) class I (MICA).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nonadherence to immunosuppressive therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> –<strong> </strong>Acute rejection can be detected in otherwise asymptomatic patients who are undergoing routine surveillance testing, or it can manifest as signs and symptoms of cardiac dysfunction that range from mild heart failure (HF) and palpitations to cardiogenic shock and syncope.</p><p></p><p class="bulletIndent1">In otherwise asymptomatic patients who are undergoing biopsy with right heart catheterization, isolated hemodynamic abnormalities are an uncommon presentation of rejection. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surveillance for rejection in asymptomatic patients</strong> –<strong> </strong>In asymptomatic patients who underwent cardiac transplantation in the last year, our approach to surveillance testing with endomyocardial biopsy and serologic testing is described in a table (<a class="graphic graphic_table graphicRef140149" href="/d/graphic/140149.html" rel="external">table 1</a>). This schedule may be modified to wean a patient from steroids more rapidly or in response to other significant changes in maintenance immunosuppression (eg, reduction of <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> levels to prevent kidney injury). (See <a class="local">'Surveillance in asymptomatic patients'</a> above.)</p><p></p><p class="bulletIndent1">Some programs continue routine surveillance testing (eg, biopsies or serologic testing) every three to four months in the second year. Surveillance biopsies are rarely conducted beyond two years, though surveillance in this period for some patients with significant risk factors for rejection may be reasonable. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Testing for rejection in symptomatic patients</strong> – In symptomatic patients with a history of alterations to immunosuppression, evidence of new cardiac abnormalities on initial testing, or whose symptoms are unexplained and suspicious for rejection, we typically perform an endomyocardial biopsy to assess for rejection. In these patients, a gene expression profiling (GEP) test or a donor-derived cell-free (dd-CF) DNA test are not substitutes for an endomyocardial biopsy. (See <a class="local">'Symptomatic patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other indications for rejection testing</strong> – In patients who have changes to their immunosuppressive regimen (eg, dose reduction in <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> or glucocorticoids, change from tacrolimus to <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a>) or who have recovered from an episode of acute rejection, we typically perform an endomyocardial biopsy one to two weeks after the change in therapy or after the rejection event to assess for rejection [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1">In some patients with small changes in therapy or low-grade rejection, either a GEP test or a dd-CF DNA test is a reasonable alternative to endomyocardial biopsy. (See <a class="local">'Other indications for testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical diagnosis</strong> – In patients who have undergone heart transplantation, the presence of new HF symptoms, unexplained arrhythmias, objective decline in cardiac function, or hemodynamic signs of acute rejection (eg, elevated filling pressures) suggest the presence of acute rejection. (See <a class="local">'Clinical diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pathologic diagnosis</strong> – The diagnosis of rejection is confirmed by pathologic examination of myocardium sampled from an endomyocardial biopsy. The examination may reveal acute cellular rejection (ACR) (<a class="graphic graphic_table graphicRef51982" href="/d/graphic/51982.html" rel="external">table 2</a>), antibody-mediated rejection (AMR), or both. (See <a class="local">'Acute cellular rejection'</a> above and <a class="local">'Acute antibody-mediated (humoral) rejection'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Khush KK, Cherikh WS, Chambers DC, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-fifth Adult Heart Transplantation Report-2018; Focus Theme: Multiorgan Transplantation. J Heart Lung Transplant 2018; 37:1155.</a></li><li><a class="nounderline abstract_t">Khush KK, Cherikh WS, Chambers DC, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult heart transplantation report - 2019; focus theme: Donor and recipient size match. J Heart Lung Transplant 2019; 38:1056.</a></li><li><a class="nounderline abstract_t">Grauhan O, Müller J, v Baeyer H, et al. Treatment of humoral rejection after heart transplantation. J Heart Lung Transplant 1998; 17:1184.</a></li><li><a class="nounderline abstract_t">Behr TM, Feucht HE, Richter K, et al. Detection of humoral rejection in human cardiac allografts by assessing the capillary deposition of complement fragment C4d in endomyocardial biopsies. J Heart Lung Transplant 1999; 18:904.</a></li><li><a class="nounderline abstract_t">Reed EF, Demetris AJ, Hammond E, et al. Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant 2006; 25:153.</a></li><li><a class="nounderline abstract_t">Taylor DO, Yowell RL, Kfoury AG, et al. Allograft coronary artery disease: clinical correlations with circulating anti-HLA antibodies and the immunohistopathologic pattern of vascular rejection. J Heart Lung Transplant 2000; 19:518.</a></li><li><a class="nounderline abstract_t">Kubo SH, Naftel DC, Mills RM Jr, et al. Risk factors for late recurrent rejection after heart transplantation: a multiinstitutional, multivariable analysis. Cardiac Transplant Research Database Group. J Heart Lung Transplant 1995; 14:409.</a></li><li><a class="nounderline abstract_t">Kobashigawa JA, Kirklin JK, Naftel DC, et al. Pretransplantation risk factors for acute rejection after heart transplantation: a multiinstitutional study. The Transplant Cardiologists Research Database Group. J Heart Lung Transplant 1993; 12:355.</a></li><li><a class="nounderline abstract_t">Jarcho J, Naftel DC, Shroyer TW, et al. Influence of HLA mismatch on rejection after heart transplantation: a multiinstitutional study. The Cardiac Transplant Research Database Group. J Heart Lung Transplant 1994; 13:583.</a></li><li><a class="nounderline abstract_t">Opelz G. Effect of HLA matching in heart transplantation. Collaborative Heart Transplant Study. Transplant Proc 1989; 21:794.</a></li><li><a class="nounderline abstract_t">DiSesa VJ, Kuo PC, Horvath KA, et al. HLA histocompatibility affects cardiac transplant rejection and may provide one basis for organ allocation. Ann Thorac Surg 1990; 49:220.</a></li><li><a class="nounderline abstract_t">Sheldon S, Yonan NA, Aziz TN, et al. The influence of histocompatibility on graft rejection and graft survival within a single center population of heart transplant recipients. Transplantation 1999; 68:515.</a></li><li><a class="nounderline abstract_t">Valenzuela NM, Reed EF. Antibodies in transplantation: the effects of HLA and non-HLA antibody binding and mechanisms of injury. Methods Mol Biol 2013; 1034:41.</a></li><li><a class="nounderline abstract_t">Ringewald JM, Gidding SS, Crawford SE, et al. Nonadherence is associated with late rejection in pediatric heart transplant recipients. J Pediatr 2001; 139:75.</a></li><li><a class="nounderline abstract_t">Tumin D, McConnell PI, Galantowicz M, et al. Reported Nonadherence to Immunosuppressive Medication in Young Adults After Heart Transplantation: A Retrospective Analysis of a National Registry. Transplantation 2017; 101:421.</a></li><li><a class="nounderline abstract_t">Scott CD, Dark JH, McComb JM. Arrhythmias after cardiac transplantation. Am J Cardiol 1992; 70:1061.</a></li><li><a class="nounderline abstract_t">Cui G, Tung T, Kobashigawa J, et al. Increased incidence of atrial flutter associated with the rejection of heart transplantation. Am J Cardiol 2001; 88:280.</a></li><li><a class="nounderline abstract_t">Bhalodolia R, Cortese C, Graham M, Hauptman PJ. Fulminant acute cellular rejection with negative findings on endomyocardial biopsy. J Heart Lung Transplant 2006; 25:989.</a></li><li><a class="nounderline abstract_t">Veiga Barreiro A, Crespo Leiro M, Doménech García N, et al. Severe cardiac allograft dysfunction without endomyocardial biopsy signs of cellular rejection: incidence and management. Transplant Proc 2004; 36:778.</a></li><li><a class="nounderline abstract_t">Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005; 24:1710.</a></li><li><a class="nounderline abstract_t">Alharethi R, Bader F, Kfoury AG, et al. Tricuspid valve replacement after cardiac transplantation. J Heart Lung Transplant 2006; 25:48.</a></li><li><a class="nounderline abstract_t">Chan MC, Giannetti N, Kato T, et al. Severe tricuspid regurgitation after heart transplantation. J Heart Lung Transplant 2001; 20:709.</a></li><li><a class="nounderline abstract_t">Deng MC, Eisen HJ, Mehra MR, et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant 2006; 6:150.</a></li><li><a class="nounderline abstract_t">Crespo-Leiro MG, Stypmann J, Schulz U, et al. Clinical usefulness of gene-expression profile to rule out acute rejection after heart transplantation: CARGO II. Eur Heart J 2016; 37:2591.</a></li><li><a class="nounderline abstract_t">Snyder TM, Khush KK, Valantine HA, Quake SR. Universal noninvasive detection of solid organ transplant rejection. Proc Natl Acad Sci U S A 2011; 108:6229.</a></li><li><a class="nounderline abstract_t">De Vlaminck I, Valantine HA, Snyder TM, et al. Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection. Sci Transl Med 2014; 6:241ra77.</a></li><li><a class="nounderline abstract_t">Hidestrand M, Tomita-Mitchell A, Hidestrand PM, et al. Highly sensitive noninvasive cardiac transplant rejection monitoring using targeted quantification of donor-specific cell-free deoxyribonucleic acid. J Am Coll Cardiol 2014; 63:1224.</a></li><li><a class="nounderline abstract_t">Agbor-Enoh S, Shah P, Tunc I, et al. Cell-Free DNA to Detect Heart Allograft Acute Rejection. Circulation 2021; 143:1184.</a></li><li><a class="nounderline abstract_t">Pham MX, Teuteberg JJ, Kfoury AG, et al. Gene-expression profiling for rejection surveillance after cardiac transplantation. N Engl J Med 2010; 362:1890.</a></li><li><a class="nounderline abstract_t">Kobashigawa J, Patel J, Kittleson M, et al. Results of a randomized trial of allomap vs heart biopsy in the first year after heart transplant: Early invasive monitoring attenuation through gene expression profiling trial. J Heart Lung Transplant 2013; 32:s203.</a></li><li><a class="nounderline abstract_t">Kobashigawa J, Patel J, Azarbal B, et al. Randomized pilot trial of gene expression profiling versus heart biopsy in the first year after heart transplant: early invasive monitoring attenuation through gene expression trial. Circ Heart Fail 2015; 8:557.</a></li><li><a class="nounderline abstract_t">Fitzsimons SJ, Evans JDW, Rassl DM, et al. High-sensitivity Cardiac Troponin Is Not Associated With Acute Cellular Rejection After Heart Transplantation. Transplantation 2022; 106:1024.</a></li><li><a class="nounderline abstract_t">Damodaran A, Dardas T, Wu AH, et al. Changes in serial B-type natriuretic peptide level independently predict cardiac allograft rejection. J Heart Lung Transplant 2012; 31:708.</a></li><li><a class="nounderline abstract_t">Moidl R, Chevtchik O, Simon P, et al. Noninvasive monitoring of peak filling rate with acoustic quantification echocardiography accurately detects acute cardiac allograft rejection. J Heart Lung Transplant 1999; 18:194.</a></li><li><a class="nounderline abstract_t">Valantine HA, Yeoh TK, Gibbons R, et al. Sensitivity and specificity of diastolic indexes for rejection surveillance: temporal correlation with endomyocardial biopsy. J Heart Lung Transplant 1991; 10:757.</a></li><li><a class="nounderline abstract_t">StGoar FG, Gibbons R, Schnittger I, et al. Left ventricular diastolic function. Doppler echocardiographic changes soon after cardiac transplantation. Circulation 1990; 82:872.</a></li><li><a class="nounderline abstract_t">Mankad S, Murali S, Kormos RL, et al. Evaluation of the potential role of color-coded tissue Doppler echocardiography in the detection of allograft rejection in heart transplant recipients. Am Heart J 1999; 138:721.</a></li><li><a class="nounderline abstract_t">Butler CR, Thompson R, Haykowsky M, et al. Cardiovascular magnetic resonance in the diagnosis of acute heart transplant rejection: a review. J Cardiovasc Magn Reson 2009; 11:7.</a></li><li><a class="nounderline abstract_t">Taylor AJ, Vaddadi G, Pfluger H, et al. Diagnostic performance of multisequential cardiac magnetic resonance imaging in acute cardiac allograft rejection. Eur J Heart Fail 2010; 12:45.</a></li><li><a class="nounderline abstract_t">Eisen HJ, Eisenberg SB, Saffitz JE, et al. Noninvasive detection of rejection of transplanted hearts with indium-111-labeled lymphocytes. Circulation 1987; 75:868.</a></li><li><a class="nounderline abstract_t">Hesse B, Mortensen SA, Folke M, et al. Ability of antimyosin scintigraphy monitoring to exclude acute rejection during the first year after heart transplantation. J Heart Lung Transplant 1995; 14:23.</a></li><li><a class="nounderline abstract_t">Narula J, Acio ER, Narula N, et al. Annexin-V imaging for noninvasive detection of cardiac allograft rejection. Nat Med 2001; 7:1347.</a></li><li><a class="nounderline abstract_t">Stehlik J, Starling RC, Movsesian MA, et al. Utility of long-term surveillance endomyocardial biopsy: a multi-institutional analysis. J Heart Lung Transplant 2006; 25:1402.</a></li><li class="breakAll">https://ishlt.org/ishlt/media/documents/SARS-CoV-2_-Guidance-for-Cardiothoracic-Transplant-and-VAD-centers.pdf (Accessed on May 22, 2020).</li><li><a class="nounderline abstract_t">Winters GL, Marboe CC, Billingham ME. The International Society for Heart and Lung Transplantation grading system for heart transplant biopsy specimens: clarification and commentary. J Heart Lung Transplant 1998; 17:754.</a></li><li><a class="nounderline abstract_t">Billingham ME, Cary NR, Hammond ME, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant 1990; 9:587.</a></li><li><a class="nounderline abstract_t">Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004; 4:1033.</a></li><li><a class="nounderline abstract_t">Joyce DL, Southard RE, Torre-Amione G, et al. Impact of left ventricular assist device (LVAD)-mediated humoral sensitization on post-transplant outcomes. J Heart Lung Transplant 2005; 24:2054.</a></li><li><a class="nounderline abstract_t">See SB, Mantell BS, Clerkin KJ, et al. Profiling non-HLA antibody responses in antibody-mediated rejection following heart transplantation. Am J Transplant 2020; 20:2571.</a></li><li><a class="nounderline abstract_t">Zhang Q, Hickey M, Drogalis-Kim D, et al. Understanding the Correlation Between DSA, Complement Activation, and Antibody-Mediated Rejection in Heart Transplant Recipients. Transplantation 2018; 102:e431.</a></li><li><a class="nounderline abstract_t">Berry GJ, Burke MM, Andersen C, et al. The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 2013; 32:1147.</a></li><li><a class="nounderline abstract_t">Fyfe B, Loh E, Winters GL, et al. Heart transplantation-associated perioperative ischemic myocardial injury. Morphological features and clinical significance. Circulation 1996; 93:1133.</a></li><li><a class="nounderline abstract_t">Joshi A, Masek MA, Brown BW Jr, et al. "Quilty" revisited: a 10-year perspective. Hum Pathol 1995; 26:547.</a></li><li><a class="nounderline abstract_t">Gonwa TA, Capehart JE, Pilcher JW, Alivizatos PA. Cytomegalovirus myocarditis as a cause of cardiac dysfunction in a heart transplant recipient. Transplantation 1989; 47:197.</a></li><li><a class="nounderline abstract_t">Eisen HJ, Hicks D, Kant JA, et al. Diagnosis of posttransplantation lymphoproliferative disorder by endomyocardial biopsy in a cardiac allograft recipient. J Heart Lung Transplant 1994; 13:241.</a></li></ol></div><div id="topicVersionRevision">Topic 3519 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30293612" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-fifth Adult Heart Transplantation Report-2018; Focus Theme: Multiorgan Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31548031" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult heart transplantation report - 2019; focus theme: Donor and recipient size match.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9883759" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Treatment of humoral rejection after heart transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10528753" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Detection of humoral rejection in human cardiac allografts by assessing the capillary deposition of complement fragment C4d in endomyocardial biopsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16446213" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Acute antibody-mediated rejection of cardiac transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10867330" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Allograft coronary artery disease: clinical correlations with circulating anti-HLA antibodies and the immunohistopathologic pattern of vascular rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7654724" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Risk factors for late recurrent rejection after heart transplantation: a multiinstitutional, multivariable analysis. Cardiac Transplant Research Database Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8329404" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Pretransplantation risk factors for acute rejection after heart transplantation: a multiinstitutional study. The Transplant Cardiologists Research Database Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7947874" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Influence of HLA mismatch on rejection after heart transplantation: a multiinstitutional study. The Cardiac Transplant Research Database Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2650297" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Effect of HLA matching in heart transplantation. Collaborative Heart Transplant Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2306143" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : HLA histocompatibility affects cardiac transplant rejection and may provide one basis for organ allocation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10480409" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The influence of histocompatibility on graft rejection and graft survival within a single center population of heart transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23775730" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Antibodies in transplantation: the effects of HLA and non-HLA antibody binding and mechanisms of injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11445797" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Nonadherence is associated with late rejection in pediatric heart transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26950728" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Reported Nonadherence to Immunosuppressive Medication in Young Adults After Heart Transplantation: A Retrospective Analysis of a National Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1384302" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Arrhythmias after cardiac transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11472708" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Increased incidence of atrial flutter associated with the rejection of heart transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16890123" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Fulminant acute cellular rejection with negative findings on endomyocardial biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15110660" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Severe cardiac allograft dysfunction without endomyocardial biopsy signs of cellular rejection: incidence and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16297770" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16399530" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Tricuspid valve replacement after cardiac transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11448795" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Severe tricuspid regurgitation after heart transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16433769" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26746629" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Clinical usefulness of gene-expression profile to rule out acute rejection after heart transplantation: CARGO II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21444804" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Universal noninvasive detection of solid organ transplant rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24944192" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24140666" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Highly sensitive noninvasive cardiac transplant rejection monitoring using targeted quantification of donor-specific cell-free deoxyribonucleic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33435695" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Cell-Free DNA to Detect Heart Allograft Acute Rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20413602" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Gene-expression profiling for rejection surveillance after cardiac transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Results of a randomized trial of allomap vs heart biopsy in the first year after heart transplant: Early invasive monitoring attenuation through gene expression profiling trial</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25697852" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Randomized pilot trial of gene expression profiling versus heart biopsy in the first year after heart transplant: early invasive monitoring attenuation through gene expression trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34241986" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : High-sensitivity Cardiac Troponin Is Not Associated With Acute Cellular Rejection After Heart Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22502810" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Changes in serial B-type natriuretic peptide level independently predict cardiac allograft rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10328144" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Noninvasive monitoring of peak filling rate with acoustic quantification echocardiography accurately detects acute cardiac allograft rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1958683" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Sensitivity and specificity of diastolic indexes for rejection surveillance: temporal correlation with endomyocardial biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2394008" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Left ventricular diastolic function. Doppler echocardiographic changes soon after cardiac transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10502219" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Evaluation of the potential role of color-coded tissue Doppler echocardiography in the detection of allograft rejection in heart transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19284612" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Cardiovascular magnetic resonance in the diagnosis of acute heart transplant rejection: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20023044" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Diagnostic performance of multisequential cardiac magnetic resonance imaging in acute cardiac allograft rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3030580" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Noninvasive detection of rejection of transplanted hearts with indium-111-labeled lymphocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7727472" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Ability of antimyosin scintigraphy monitoring to exclude acute rejection during the first year after heart transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11726976" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Annexin-V imaging for noninvasive detection of cardiac allograft rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17178332" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Utility of long-term surveillance endomyocardial biopsy: a multi-institutional analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17178332" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Utility of long-term surveillance endomyocardial biopsy: a multi-institutional analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9730423" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The International Society for Heart and Lung Transplantation grading system for heart transplant biopsy specimens: clarification and commentary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2277293" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15196059" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : National conference to assess antibody-mediated rejection in solid organ transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16364849" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Impact of left ventricular assist device (LVAD)-mediated humoral sensitization on post-transplant outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32190967" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Profiling non-HLA antibody responses in antibody-mediated rejection following heart transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29916988" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Understanding the Correlation Between DSA, Complement Activation, and Antibody-Mediated Rejection in Heart Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24263017" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8653833" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Heart transplantation-associated perioperative ischemic myocardial injury. Morphological features and clinical significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7750939" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : "Quilty" revisited: a 10-year perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2536201" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Cytomegalovirus myocarditis as a cause of cardiac dysfunction in a heart transplant recipient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8031806" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Diagnosis of posttransplantation lymphoproliferative disorder by endomyocardial biopsy in a cardiac allograft recipient.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
